
BioCircuit Technologies: Innovating noninvasive devices for peripheral nerve monitoring and repair.
Founded with a mission to revolutionize nerve care, BioCircuit Technologies focuses on developing noninvasive electrophysiology devices aimed at monitoring, controlling, and repairing peripheral nerves. Their core vision is to enhance patient outcomes through innovative medical technologies that simplify and improve the treatment of nerve-related conditions. The company offers advanced products such as sutureless self-adhering wraps designed to protect repair sites and minimize tissue adhesions, ensuring precise alignment and effective nerve regeneration.
BioCircuit Technologies has garnered attention from notable investors and industry experts who recognize the potential impact of their groundbreaking solutions. The company has achieved significant milestones, including clinically proven materials and successful cadaveric usability studies, which validate the efficacy of their devices. By addressing the complexities and challenges of nerve repair, BioCircuit Technologies is making a substantial impact in the medical field, improving the quality of life for patients with peripheral nerve injuries.
Companies similar to BioCircuit Technologies include Renerva, Checkpoint Surgical, Neuright and Neuraptive Therapeutics.
BioCircuit Technologies was founded in 2016.
BioCircuit Technologies' headquarters is located in Atlanta, GA, US.
BioCircuit Technologies' most recent funding round was for $2.4M (USD) in October 2023.
As of Oct 19, 2023, BioCircuit Technologies has disclosed funding of $14.6M (USD). Undisclosed round amounts are excluded.
BioCircuit Technologies has 23 employees as of Feb 5, 2024.
Neuraptive Therapeutics
neuraptive.com